HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Huayuan Medical Group Holding - How to Tell a Good Story After the COVID-19 Magic Disappear?

Pre-IPO Top Glove Corp - The Good Times Brought by COVID-19 Are Slipping Away

Intco Medical Technology (300677.CH) - Declining Performance & Overcapacity Indicate Gloomy Outlook

Wuxi Biologics (2269.HK) 2021Q3 - The Strength and the Concerns Behind the New Full-Year Guidance

Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns

WuXi AppTec (2359.HK/603259.CH) 2021Q3 - Logic Change?

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/adlai-nortye-ltd" target="_blank" data-smartkarma-citation="entities:34049:1" rel="noopener">Adlai Nortye (ADN HK)</a> is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies for patients across various stages of tumors.</li>
<li> This article mainly analyzed the clinical-stage drug candidates in the pipeline, including AN2025, AN0025, AN1004, AN4005 and others.</li>
<li>Due to the concerns on early-stage pipeline, commercialization prospect, policy risks and the market's attitude towards license-in mode, we are conservative about the outlook of the Company at the current stage. </li>
</ul>



Adlai Nortye (ADN HK) is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies for patients across various stages of tumors.
 This article mainly analyzed the clinical-stage drug candidates in the pipeline, including AN2025, AN0025, AN1004, AN4005 and others.
Due to the concerns on early-stage pipeline, commercialization prospect, policy risks and the market's attitude towards license-in mode, we are conservative about the outlook of the Company at the current stage. 


Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns